Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 54

1.

Occult Colonic Adenocarcinoma as a Cause of Recurrent Hepatic Encephalopathy in Cirrhosis.

Petrikova J, Janicko M, Jarcuska P.

Isr Med Assoc J. 2019 Sep;21(9):629-631. No abstract available.

2.

Noninvasive Assessment of Liver Fibrosis in Patients with Chronic Hepatitis B or C by Contrast-Enhanced Magnetic Resonance Imaging.

Hako R, Kristian P, Jarčuška P, Haková I, Hockicková I, Schréter I, Janičko M.

Can J Gastroenterol Hepatol. 2019 Apr 1;2019:3024630. doi: 10.1155/2019/3024630. eCollection 2019.

3.

Chronic Viral Hepatitis and Metabolic Syndrome/Cardiovascular Risk.

Jarcuska P, Abdel-Razik A, Flisiak R, Singh RB.

Can J Gastroenterol Hepatol. 2018 Nov 4;2018:7369314. doi: 10.1155/2018/7369314. eCollection 2018. No abstract available.

4.

Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals.

Drazilova S, Janicko M, Skladany L, Kristian P, Oltman M, Szantova M, Krkoska D, Mazuchova E, Piesecka L, Vahalova V, Rac M, Schreter I, Virag L, Koller T, Liptakova A, Ondrasova M, Jarcuska P.

Can J Gastroenterol Hepatol. 2018 Oct 3;2018:6095097. doi: 10.1155/2018/6095097. eCollection 2018.

5.

Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy.

Drazilova S, Gazda J, Janicko M, Jarcuska P.

Can J Gastroenterol Hepatol. 2018 Aug 13;2018:6150861. doi: 10.1155/2018/6150861. eCollection 2018. Review.

6.

Serum Uric Acid in Roma and Non-Roma-Its Correlation with Metabolic Syndrome and Other Variables.

Petrikova J, Janicko M, Fedacko J, Drazilova S, Madarasova Geckova A, Marekova M, Pella D, Jarcuska P.

Int J Environ Res Public Health. 2018 Jul 4;15(7). pii: E1412. doi: 10.3390/ijerph15071412.

7.

Prevalence and Risk Factors for Hepatitis B Virus Infection in Roma and Non-Roma People in Slovakia.

Drazilova S, Janicko M, Kristian P, Schreter I, Halanova M, Urbancikova I, Madarasova-Geckova A, Marekova M, Pella D, Jarcuska P; HepaMeta Team.

Int J Environ Res Public Health. 2018 May 22;15(5). pii: E1047. doi: 10.3390/ijerph15051047.

8.

Seroprevalence of Hepatitis E Virus in Roma Settlements: A Comparison with the General Population in Slovakia.

Halánová M, Veseliny E, Kalinová Z, Jarčuška P, Janičko M, Urbančíková I, Pella D, Dražilová S, Babinská I; HepaMeta Team.

Int J Environ Res Public Health. 2018 May 3;15(5). pii: E904. doi: 10.3390/ijerph15050904.

9.

Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.

Polaris Observatory Collaborators.

Lancet Gastroenterol Hepatol. 2018 Jun;3(6):383-403. doi: 10.1016/S2468-1253(18)30056-6. Epub 2018 Mar 27. Review.

PMID:
29599078
10.

On the Structure of Mortality among the Regions in the Slovak Republic.

Kubák M, Gavurová B, Jarčuška P, Janičko M.

Cent Eur J Public Health. 2017 Dec;25 Suppl 2:S23-S30. doi: 10.21101/cejph.a4957.

11.

Mortality Amenable to Health Care in European Union Countries and Its Limitations.

Jarčuška P, Janičko M, Barták M, Gavurová B, Vagašová T.

Cent Eur J Public Health. 2017 Dec;25 Suppl 2:S16-S22. doi: 10.21101/cejph.a4956.

12.

The Impact of Selected Groups of Non-communicable Disease Deaths on Life Expectancy in the Slovak Republic.

Gavurová B, Vagašová T, Dražilová S, Jarčuška P.

Cent Eur J Public Health. 2017 Dec;25 Suppl 2:S4-S9. doi: 10.21101/cejph.a4954.

13.

The Slovak Republic needs to improve health of the population.

Jarčuška P.

Cent Eur J Public Health. 2017 Dec;25 Suppl 2:S3.

PMID:
29524362
14.

Exposure to Toxoplasma gondii in the Roma and Non-Roma Inhabitants of Slovakia: A Cross-Sectional Seroprevalence Study.

Antolová D, Janičko M, Halánová M, Jarčuška P, Gecková AM, Babinská I, Kalinová Z, Pella D, Mareková M, Veseliny E; HepaMeta Team.

Int J Environ Res Public Health. 2018 Feb 27;15(3). pii: E408. doi: 10.3390/ijerph15030408.

15.

A Community-Based Study to Estimate the Seroprevalence of Trichinellosis and Echinococcosis in the Roma and Non-Roma Population of Slovakia.

Antolová D, Halánová M, Janičko M, Jarčuška P, Reiterová K, Jarošová J, Madarasová Gecková A, Pella D, Dražilová S; HepaMeta Team.

Int J Environ Res Public Health. 2018 Feb 2;15(2). pii: E251. doi: 10.3390/ijerph15020251.

16.

Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe.

Marshall AD, Cunningham EB, Nielsen S, Aghemo A, Alho H, Backmund M, Bruggmann P, Dalgard O, Seguin-Devaux C, Flisiak R, Foster GR, Gheorghe L, Goldberg D, Goulis I, Hickman M, Hoffmann P, Jancorienė L, Jarcuska P, Kåberg M, Kostrikis LG, Makara M, Maimets M, Marinho RT, Matičič M, Norris S, Ólafsson S, Øvrehus A, Pawlotsky JM, Pocock J, Robaeys G, Roncero C, Simonova M, Sperl J, Tait M, Tolmane I, Tomaselli S, van der Valk M, Vince A, Dore GJ, Lazarus JV, Grebely J; International Network on Hepatitis in Substance Users (INHSU).

Lancet Gastroenterol Hepatol. 2018 Feb;3(2):125-133. doi: 10.1016/S2468-1253(17)30284-4. Epub 2017 Oct 3.

PMID:
28986139
17.

Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.

Polaris Observatory HCV Collaborators.

Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176. doi: 10.1016/S2468-1253(16)30181-9. Epub 2016 Dec 16. Review.

PMID:
28404132
18.

Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.

European Union HCV Collaborators.

Lancet Gastroenterol Hepatol. 2017 May;2(5):325-336. doi: 10.1016/S2468-1253(17)30045-6. Epub 2017 Mar 15.

PMID:
28397696
19.

Pleiotropic effects of statins in the diseases of the liver.

Janicko M, Drazilova S, Pella D, Fedacko J, Jarcuska P.

World J Gastroenterol. 2016 Jul 21;22(27):6201-13. doi: 10.3748/wjg.v22.i27.6201. Review.

20.

Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort.

Foster GR, Coppola C, Derbala M, Ferenci P, Orlandini A, Reddy KR, Tallarico L, Shiffman ML, Ahlers S, Bakalos G, Hassanein T; GUARD-C Study Group.

PLoS One. 2016 Mar 28;11(3):e0151703. doi: 10.1371/journal.pone.0151703. eCollection 2016.

Supplemental Content

Loading ...
Support Center